Greek English Arabic Arabic Romanian Russian
AABB Accredited
Lifeline
Tuesday, 28 March 2017
The first and largest family Umbilical Cord Blood and Tissue Bank in Cyprus.


Quick Search:
 
Enrol with Lifeline Lifeline Advantages Video Center Contact Lifeline Brochure
About Us
Umbilical Cord Blood
Umbilical Cord Tissue
Regenerative Medicine
Lifeline Service
Stem Cell Collection
Laboratory Facilities
Lifeline News
Media and Video News
Media News
Video Center
Regulations & Directives
FAQs
Contact Us
AABB Accredited
European Business Awards 2014-15
Lifeline, Winner of the Cyprus Innovation Award - Services Sector 2010

Stem Cell Therapy Following Meniscus Knee Surgery May Reduce Pain, Restore Meniscus



First study of its kind found no “clinically important” safety issues with treatment

 

Rosemont, Ill. - A single stem cell injection following meniscus knee surgery may provide pain relief and aid in meniscus regrowth, according to a novel study appearing in the January issue of the Journal of Bone and Joint Surgery(JBJS).

 

More than one million knee arthroscopy procedures are performed each year in the U.S. primarily for the treatment of tears to the meniscus – the wedge-shaped pieces of cartilage that act as "shock absorbers" between the thighbone and shinbone in the knee joint.

 

In the first-of-its-kind study, “Adult Human Mesenchymal Stem Cells (MSC) Delivered via Intra-Articular Injection to the Knee, Following Partial Medial Meniscectomy,” most patients who received a single injection of adult stem cells following the surgical removal of all or part of a torn meniscus, reported a significant reduction in pain. Some patients-24 percent of one MSC group and 6 percent of another-experienced at least a 15 percent increase in meniscal volume at one year. There was no additional increase in meniscal volume at year two.

 

“The results demonstrated that high doses of mesenchymal stem cells can be safely delivered in a concentrated manner to a knee joint without abnormal tissue formation,” said lead study author C. Thomas Vangsness, Jr., MD. “No one has ever done that before.” In addition, “the patients with arthritis got strong improvement in pain” and some experienced meniscal regrowth.

 

 

Specific Study Details

The study involved 55 patients, ages 18 to 60, who underwent a partial medial meniscectomy (the surgical removal of all or part of a torn meniscus) at seven medical institutions. Patients were randomly placed in one of three treatment groups: Group A patients (18) received a “low-dose” injection of 50 million stem cells within seven to 10 days after meniscus surgery; Group B patients (18), a higher dose of 150 million stem cells; and the “control group (19),” sodium hyaluronate only. Patients were assessed to evaluate safety, meniscus regeneration through MRI and X-ray images, overall condition of the knee joint and clinical outcomes through two years. While most of the patients had some arthritis, patients with severe (level three or four) arthritis, in the same compartment as the meniscectomy, were excluded from the study.

 

 

Key Study Findings

  • There was no abnormal (ectopic) tissue formation or “clinically important” safety issues identified.
  • There was “significantly increased meniscal volume,” determined by an MRI in 24 percent of the patients in the low-dose injection group (A) and six percent of the high-dose injection group (B) at one year. There was no statistical increase in meniscal volume at two years.
  • No patients in the control group (non-MSC group) met the 15 percent threshold for increased meniscal volume.
  • Patients with osteoarthritis experienced a reduction in pain in the stem cell treatment groups; there was no reduction in pain in the control (non-MSC group).  

“The results of this study suggest that mesenchymal stem cells have the potential to improve the overall condition of the knee joint,” said Dr. Vangsness. “I am very excited and encouraged” by the results. With the success of a single injection, “it begs the question: What if we give a series of injections?”

 

http://newsroom.aaos.org/media-resources/Press-releases/stem-cell-therapy-following-meniscus-knee-surgery-may-reduce-pain-restore-meniscus.htm?elq=1f2676bedf6d4f52bb05f391b9b6fe28&elqCampaignId=254 

 

 

LFLN REF. 27.03.14 P.82

Enrol with Lifeline
Media and Video News
»AIDS

»Anemias

»Autism

»Bone Disorders

»Cancer

»Cerebral Palsy

»Cord Blood News

»Diabetes

»Ex-Vivo Expansion

»Heart Repair

»Immunodeficiencies

»Leukemias

»Mesenchymal Cells

»Multiple Sclerosis

»Parkinson's

»Regenerative Medicine

»Spinal Cord Injuries

»Stem Cell Harvest for the Future

»Stroke/Brain Injury

Top  |  Back  |  Easy Print  |  Advanced Search  |  Contact Us  |  Home
Participation in External Quality Control Schemes
UK NEQAS International Quality Expertise Labquality AABB Accredited
Lifeline © Copyright © C.B.B. Lifeline Biotech Ltd  |  Disclaimer  |  Terms of Use Design & Development: Crucial Services Ltd